- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT01724645
Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes
Randomized, Open Label, Parallel Controlled, to Evaluate the Beneficial Effects of Korean Traditional Dites in Subjects With Hypertension and Type 2 Diabetes.
This trial is being conducted to look for following changes when Korean traditional diets is taken in subjects with hypertension and type 2 diabetes:
To evaluate the improvement of the controlling fasting blood glucose and glycated hemoglobin.
To assess the controlling blood pressure and heart rate.
To evaluate the influence on cardiovascular risk factor, Triglyceride, cholesterol, High Density Lipoprotein-cholesterol and Low-Density Lipoprotein-cholesterol.
To evaluate the influence on Gamma-Glutamyl Transpeptidase.
To evaluate the influence on Cardiovascular risk factor.
To evaluate the influence on valsava score, breathing score and upright score.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Jeollabuk-do
-
Jeonju, Jeollabuk-do, Koreai Köztársaság, 560-822
- Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Subjects who are men and women volunteers 19~80years
- Subject who have hypertension and type 2diabetes.
- Subject who have taking oral medications :
(hypoglycemic, blood pressure and lipid modifying drugs).
- Subject must provide written informed consent to participate in the study.
Exclusion Criteria:
- Subject with a history or evidence of clinically significant gastrointestinal,anorectal, hepatic, renal, neurological, pulmonary, endocrine, blood tumor,psychiatric.
- Hypertension(DBP>116mmHg or SBP>200 mmHg) having the history of cardiovascular events or taking medications known to affect lipoprotein metabolism.
- Having Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (HbA1c >9.0%).
- Subjects with the history of cancer.
- Subjects who have a gastrointestinal (GI) disease (Crohn's disease, etc.) that would increase the influence with absorbance medication or a GI surgery excluding appendectomy and hernia surgery.
- Having digestive, or central nervous system disorders.
- Subject is hematologic, or neuroretinopathy.
- Subject with uterine fibroids at ultrasonography.
- Having severe or malignant retinopathy.
- Having the impairment of renal and liver function, dysproteinemia, nephritic syndrome, or other renal disease.
- Having coagulopathy
- Having human immunodeficiency virus.
- Having the history of mental instability and of drug and alcohol.
- Having the history of reactions to our experimental products.
- Participating in other clinical trials within the past 2 months.
- Having laboratory tests, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study.
- Having the history of alcohol or substance abuse.
- Subject is pregnant, planning to become pregnant, or breast-feeding.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Korean traditional diets
Korean traditional diets (calorie 2,100kcal) for 12weeks
|
The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely. The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods.
Más nevek:
|
|
Aktív összehasonlító: Control group
Control group : told to "eat as usal diet) for 12weeks
|
Told to " eat as usal diets".
Más nevek:
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
HbA1C :Glycated Hemoglobin
Időkeret: 84days
|
Glycated Hemoglobin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
TG :Triglycerides
Időkeret: 84days
|
Triglycerides is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
TC :Total cholesterol
Időkeret: 84days
|
Total cholesterol is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
HDL-C :High Density Lipoprotein-Cholesterol
Időkeret: 84days
|
HDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
LDL-C : Low Density Lipoprotein-Cholesterol
Időkeret: 84days
|
LDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
Breathing score
Időkeret: 84days
|
Breathing score is measured in study visits to the clinic, week 0(baseline)and week 12.
|
84days
|
|
Valsalva score
Időkeret: 84days
|
Valsalva score is measured in study visits to the clinic, week 0(baseline)and week 12.
|
84days
|
|
Upright score
Időkeret: 84days
|
Upright score is measured in study visits to the clinic, week 0(baseline) and week 12.
|
84days
|
|
ApoA1 :Apolipoprotein A1
Időkeret: 84days
|
Apolipoprotein A1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
ApoB :Apolipoprotein B
Időkeret: 84days
|
Apolipoprotein B is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
Apo E :Apolipoprotein E
Időkeret: 84days
|
Apolipoprotein E is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
Free fatty acid
Időkeret: 84days
|
Free fatty acid is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
Adiponectin
Időkeret: 84days
|
Adiponectin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
PAI-1 :Plasminogen activator inhibitor type 1
Időkeret: 84days
|
PAI-1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
Homocysteine
Időkeret: 84days
|
Homocysteine is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
FPG :Fasting plasma glucose
Időkeret: 84days
|
Fasting plasma glucose is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
DBP:Diastolic Blood Pressure
Időkeret: 84days
|
DBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
SBP:Systolic Blood Pressure
Időkeret: 84days
|
SBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
Heart rate
Időkeret: 84days
|
Heart rate is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
Egyéb eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
weight
Időkeret: 84days
|
weight is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
BMI:Body Mass Index
Időkeret: 84days
|
BMI is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
Body fat percent
Időkeret: 84days
|
Body fat percent is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
Waist
Időkeret: 84days
|
Waist is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
|
84days
|
|
Obesity associated gut microbiome(Bacteriodetes)
Időkeret: 84days
|
Bacteriodetes is measured in study visits to the clinic, week 0(baseline)and week 12.
|
84days
|
|
Obesity associated gut microbiome(Firmicutes)
Időkeret: 84days
|
Firmicutes is measured in study visits to the clinic, week 0(baseline)and week 12.
|
84days
|
|
Hypoglycemic(oral medication)
Időkeret: 84days
|
Hypoglycemic oral medication is measured in study 0wk, 4wk, 8wk and 12wk.
|
84days
|
|
Control blood pressure(oral medication)
Időkeret: 84days
|
Control blood pressure(oral medication) is measured in study 0wk, 4wk, 8wk and 12wk.
|
84days
|
|
Lipid modifying (oral medication)
Időkeret: 84days
|
Lipid modifying (oral medication) is measured in study 0wk, 4wk, 8wk and 12wk.
|
84days
|
Együttműködők és nyomozók
Szponzor
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Becslés)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- CUH_KOREAN-FOOD_2-2_2010
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .